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Background: Polylactic-co-glycolic acid (PLGA) nanoparticles have been used to increase 
the relative oral bioavailability of hydrophobic compounds and polyphenols in recent years, but 
the effects of the molecular weight of PLGA on bioavailability are still unknown. This study 
investigated the influence of polymer molecular weight on the relative oral bioavailability of 
curcumin, and explored the possible mechanism accounting for the outcome.
Methods: Curcumin encapsulated in low (5000–15,000) and high (40,000–75,000) molecular 
weight PLGA (LMw-NPC and HMw-NPC, respectively) were prepared using an emulsification-
solvent evaporation method. Curcumin alone and in the nanoformulations was administered 
orally to freely mobile rats, and blood samples were collected to evaluate the bioavailability of 
curcumin, LMw-NPC, and HMw-NPC. An ex vivo experimental gut absorption model was used 
to investigate the effects of different molecular weights of PLGA formulation on absorption of 
curcumin. High-performance liquid chromatography with diode array detection was used for 
quantification of curcumin in biosamples.
Results: There were no significant differences in particle properties between LMw-NPC and 
HMw-NPC, but the relative bioavailability of HMw-NPC was 1.67-fold and 40-fold higher 
than that of LMw-NPC and conventional curcumin, respectively. In addition, the mean peak 
concentration (Cmax) of conventional curcumin, LMw-NPC, and HMw-NPC was 0.028, 0.042, 
and 0.057 µg/mL, respectively. The gut absorption study further revealed that the HMw-PLGA 
formulation markedly increased the absorption rate of curcumin in the duodenum and resulted 
in excellent bioavailability compared with conventional curcumin and LMw-NPC.
Conclusion: Our findings demonstrate that different molecular weights of PLGA have varying 
bioavailability, contributing to changes in the absorption rate at the duodenum. The results of 
this study provide the rationale for design of a nanomedicine delivery system to enhance the 
bioavailability of water-insoluble pharmaceutical compounds and functional foods.
Keywords: absorption, duodenum, molecular weight, poly(lactic-co-glycolic acid), PLGA, 
relative oral bioavailability
Introduction
Polyphenols exist widely in plants and plant-derived foods, including vegetables, fruit, 
tea, spices, wine, beverages, and nutritional supplement products, thus constitute an 
important part of the human diet. Previous studies have demonstrated that polyphenols 
have broad pharmacological activity and biological benefits, including anticancer, neu-
roprotection, chemoprevention, and protection against cardiovascular disease.1 These 
advantages are attributed to their useful antioxidant and anti-inflammatory properties 
that regulate cell proliferation and function to prevent onset and progression of   various 
human diseases.2 However, the beneficial effects of many polyphenols on human 
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health are limited due to their low oral   bioavailability. This 
is because the polyphenols, including curcumin,3 resveratrol,4 
quercetin,5 daidzein,6 silymarin,7 and other polyphenols2 are 
poorly absorbed in the gut and undergo fast metabolism by 
the liver.
To improve the low oral bioavailability of polyphenols, 
researchers have investigated their encapsulation in different 
nanoformulation systems, including micelles, liposomes, 
and nanoparticles.2,8 The mechanism by which these nano-
formulations enhance the oral bioavailability of polyphenols 
involves increasing the surface area and interaction of the 
compounds, thereby raising the dissolution rate to improve 
their absorption.9 Nevertheless, previous studies have shown 
that polyester nanoparticle-based formulations are suitable for 
oral ingestion because they are more stable than other formu-
lations in the gastrointestinal tract.10 Polyesters, for instance, 
polylactic-co-glycolic acid (PLGA), are the substances most 
often used in nanoformulations and have been approved 
by the US Food and Drug Administration as therapeutic 
devices owing to their biocompatibility, biodegradability, and 
versatile degradation kinetics.11 Recent research has shown 
that nanoformulations based on PLGA and nanogels have 
lower human serum protein binding and are more compatible 
than β-cyclodextrin, cellulose, and dendrimers with human 
  erythrocytes.12 Accordingly, PLGA nanoparticle systems have 
been used extensively to increase the oral bioavailability of 
polyphenols. Sonaje et al have demonstrated that the oral 
bioavailability of ellagic acid is increased when it is nanofor-
mulated with PLGA.13 Another study has shown that quercetin 
encapsulated in PLGA nanoparticles has an increased ability 
to protect the liver and brain against oxidative damage.14 
Curcumin in a PLGA nanoformulation not only has increased 
oral bioavailability but is also taken up in increased amounts 
by metastatic cancer cells.3,15 Xie et al have reported that the 
improved oral bioavailability of curcumin when encapsulated 
in PLGA nanoparticles may be attributable to enhanced 
water solubility, improved permeability, and inhibition of 
P-glycoprotein-mediated efflux in the intestine.16
Although PLGA nanoformulations are effective in 
improving the oral bioavailability of polyphenols, many 
kinds of PLGA with different molecular weights are avail-
able on the market. Our knowledge about the influence of 
the molecular weight of PLGA on the oral bioavailability of 
polyphenols is limited. Hence, the aim of this work was to 
investigate the effects of the molecular weight of PLGA on 
the oral bioavailability of polyphenols. Curcumin, one of the 
biologically active polyphenols, is a candidate compound for 
further pharmacokinetic study.
Materials and methods
Chemicals and reagents
Polyvinyl alcohol (molecular weight 9000–10,000), 
low molecular weight PLGA (50:50, molecular weight 
5000–15,000), high molecular weight PLGA (50:50, molecu-
lar weight 40,000–75,000), monosodium phosphate, sucrose, 
2-(4′-hydroxybenzeneazo)benzoic acid (as the internal 
standard), and polyethylene glycol 400 were obtained from 
Sigma-Aldrich (St Louis, MO). Curcumin (purity $95%) 
was purchased from Fluka (Buchs, Switzerland). Acetonitrile 
and dichloromethane were obtained from Merck (Darmstadt, 
Germany). Milli-Q grade water (Millipore, Bedford, MA) was 
used for preparation of the mobile phase and solution.
Encapsulation of curcumin  
in PLgA nanoparticles
A high-pressure emulsification-solvent evaporation technique 
was used to encapsulate curcumin in PLGA nanoparticles, 
as reported previously.17 In brief, 50 mg of PLGA (low 
or high molecular weight) and 5 mg of curcumin were 
added to 1.25 mL of dichloromethane as the oil phase and 
sonicated for 5 minutes to dissolve all substances. This oil 
phase was added to 10 mL of aqueous phase (containing 2% 
  polyvinyl alcohol and 20% sucrose, w/v) and then homo-
genized using a   Polytron PT-MR 2100 (Kinematica AG, 
Lucerne,   Switzerland) at 28,000 rpm for 10 minutes to form 
an   emulsion. The emulsion was passed across a 0.1 µm filter 
twice at an operating pressure of 5 kg/cm2 using an acces-
sory extruder (EF-C5, Avestin, Canada) to formulate low and 
high molecular weight PLGA nanoparticles encapsulating 
curcumin (LMw-NPC and HMw-NPC, respectively). The 
resulting nanoparticles were stirred at 500 rpm overnight 
and air-dried to evaporate the organic solvent.
Characteristics of LMw-NPC  
and HMw-NPC
The particle size and polydispersity index of the LMw-NPC 
and HMw-NPC were measured by dynamic light scattering 
(90Plus, BIC, Holtsville, NY). The zeta potential of the 
LMw-NPC and HMw-NPC was determined using a zeta 
potential analyzer (90Plus, BIC).
Entrapment efficiency
To evaluate the entrapment efficiency of curcumin 
encapsulated in PLGA nanoparticles, LMw-NPC and 
HMw-NPC solutions were centrifuged at 11,000 rpm for 
15 minutes   (Centrifuge 5415R, Eppendorf, Germany). 
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After   centrifugation, the supernatant was removed and 1 mL 
of acetonitrile was then added to the nanoparticle pellet to 
destroy its structure and allow release of curcumin. The 
amount of curcumin in the nanoparticles was analyzed by 
high-performance liquid chromatography (HPLC). Percent 
entrapment efficiency is given by:
  (Curcuminencapsulated/Curcumintotal) × 100
Transmission electron microscopy
Briefly, the LMw-NPC and HMw-NPC solutions were placed 
dropwise onto a 400 mesh copper grid coated with carbon. 
About 15 minutes after nanoparticle deposition, the grid was 
patted with filter paper to remove surface water and then 
stained using a solution of phosphotungstic acid (2%, w/v) for 
20 minutes. TEM samples were obtained after the stained sam-
ple had been allowed to dry in air.   Micrographs of   LMw-NPC 
and HMw-NPC were obtained using a transmission electron 
microscope (TEM, JEM-2000EXII, JEOL, Tokyo, Japan).
HPLC system and analytical  
method validation
HPLC system
The HPLC system comprised a chromatographic pump 
(LC-20AT,  Shimadzu,  Kyoto,  Japan),  autosampler 
  (SIL-20AT, Shimadzu), diode array detector (SPD-M20A, 
Shimadzu), and degasser (DG-240). A reversed-phase C18 
column (4.6 × 150 mm, particle size 5 µm, Eclipse XDB, 
  Agilent, Palo Alto, CA) was used for the HPLC   separation. 
The mobile phase consisted of acetonitrile, 10 mM 
  monosodium phosphate (pH 3.5 adjusted by phosphoric acid, 
40:60, v/v) at a flow rate of 0.8 mL per minute. The HPLC 
run time was 27 minutes and the detection wavelength was set 
at 425 nm. The mobile phase was passed through a 0.45 µm 
Millipore membrane filter and then degassed by sonication 
2510R-DTH (Bransonic, CT) before use.
Validation of analytical method
A stock solution of curcumin was diluted in acetonitrile 500 µg/
mL to make serial concentrations of a working standard solu-
tion (0.1, 0.25, 1, 2.5, 10, and 25 µg/mL) with 50% acetonitrile. 
Calibration standards were prepared using 5 µL of the working 
standard solution spiked with 45 µL of blank plasma, feces, and 
urine. The sample extracted procedures described follow the 
sample preparation section, on the next page. The calibration 
curves were represented by the peak area ratio of curcumin to 
the internal standard spiked in blank matrix as the y axis and 
the concentration of curcumin as the x axis.
The limits of detection and quantification were defined as 
a signal-to-noise ratio of 3 and the lowest concentration of 
the linear regression, respectively. The accuracy and   precision 
of intraday (same day) and interday (six sequential days) 
sampling of curcumin were assayed (six individual tests). 
  Accuracy (% bias) was calculated as [(Cobs – Cnom)/Cnom] × 100, 
while Cnom represented the nominal concentration and Cobs 
indicated the mean value of the observed   concentration. 
  Precision was calculated as the relative standard deviation 
(RSD) from the observed concentrations as follows:
  % RSD = [standard deviation/Cobs] × 100.
The % bias and % RSD value for the lowest accept-
able reproducibility concentrations were defined as being 
within ±15%. Extraction recovery (%) of curcumin was 
assessed by comparing the peak area ratio of curcumin and 
the internal standard spiked with blank matrix three times 
(at concentrations of 0.1, 0.25, and 2.5 µg/mL) to   reference 
the curcumin prepared in 50% acetonitrile at the same 
concentrations.
Animal study
Male Sprague-Dawley rats (215 ± 10 g body weight) were 
obtained from the Laboratory Animal Center at National 
Yang-Ming University (Taipei, Taiwan). The animals were 
pathogen-free and allowed to adapt to an environmentally 
controlled habitat (24°C ± 1°C on a 12-hour light-dark 
cycle). Food (Laboratory Rodent Diet 5001, PMI Feeds Inc, 
  Richmond, IN) and water were available ad libitum. All ani-
mal experiments were performed according to the National 
Yang-Ming University guidelines, principles, and procedures 
for the care and use of laboratory animals.
The rats were anesthetized using pentobarbital 50 mg/kg 
intraperitoneally. During anesthesia, the right jugular vein 
was catheterized with polyethylene tubing for blood   sampling. 
An external cannula was fastened in the dorsal neck area. 
The rats were returned to consciousness after one day and 
could move freely. Curcumin and the LMw-NPC/HMw-NPC 
nanoformulations were administered by gavage to the rats 
at doses of 1 g/kg and 50 mg/kg, respectively. After oral 
administration, a 300 µL blood sample was obtained from 
the right jugular vein into a tube rinsed with heparin at 15, 
30, 45, 60, 90, 120, 150, 180, 240, 300, 360, and 480 minutes. 
Fecal and urine samples were collected in metabolic cages 
(Mini Mitter, Bend, OR) at 0–12, 12–24, 24–36, 36–48, and 
48–72 hours after treatment with curcumin, LMw-NPC, or 
HMw-NPC.
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Sample preparation
Blood samples were centrifuged at 8000 rpm for 10 minutes 
at 4°C for preparation of the plasma samples. The supernatant 
was collected and preserved at −20°C before analysis. The feces 
were air-dried, weighed, and then homogenized in   five-fold 
of their volume (1 g feces with 5 ml) with 50% aqueous 
acetonitrile using the Polytron PT-MR 2100 homogenizer. The 
fecal samples were then centrifuged at 6000 rpm for 10 minutes 
at 4°C, and the supernatant was then collected and preserved 
at −20°C for further assay. Plasma and fecal samples (50 µL, 
  vortex-mixed with 100 µL of internal standard solution con-
taining 1.5 µg/mL of 2-(4′-hydroxybenzeneazo)benzoic acid 
dissolved in acetonitrile) were subjected to protein   precipitation. 
After centrifugation at 12,000 rpm for 15 minutes, 20 µL of 
supernatant was collected and analyzed by HPLC.
The original volume of urine was recorded before cen-
trifugation at 8000 rpm for 10 minutes and collection of 
the supernatant. Next, 50 µL of the urine supernatant was 
extracted using 1 mL of ethyl acetate and vortexed for one 
minute. The ethyl acetate phase was collected by centrifuga-
tion (13,000 rpm for one minute), and then transferred to a 
clear glass tube. After drying by vacuum centrifugation, the 
residue was reconstituted in 100 µL of 50% internal standard 
solution, and 20 µL of the dissolved solution was injected 
into the HPLC column.
Ex vivo curcumin absorption  
using reverted rat gut sacs
The ex vivo drug absorption study was performed as pre-
vious described.18 Male Sprague-Dawley rats (210 ± 10 g 
body weight) were sacrificed by intraperitoneal over-
dose using 1 mL/kg urethane (1 g/mL) and α-chloralose 
(0.1 g/mL). The entire small intestine was quickly removed 
and douched several times with normal saline (0.9%, w/v) at 
room temperature. The intestine was put into warm (37°C) 
TC-199 medium (pH 7.4) and separated into the duodenum, 
jejunum, and ileum. The gut was then gently reverted using a 
glass rod (2.5 mm diameter). The large gut sac was divided 
into small sacs of approximately 2 cm in length, then filled 
with TC-199 medium and tied with a silk suture.
Each of the small sacs was incubated in a conical flask 
containing 19.5 mL of TC-199 medium in a gentle shaking 
water bath at 37°C. Next, 0.5 mL of curcumin 100 µg/mL, 
LMw-NPC, and HMw-NPC were added into conical flasks. 
After incubating for one hour, each sac was cut open, and the 
serosal fluid and sac tissue collected into a clear tube; 1 mL 
of acetonitrile was added to the sac tissue, which was then 
homogenized and centrifuged at 6000 rpm for 10 minutes. 
A 50 µL quantity of the sac supernatant and serosal fluid 
was added to 100 µL of internal standard   solution for 
protein precipitation and centrifuged at 13,000 rpm for 
10 minutes. The supernatants (20 µL) were collected and 
analyzed by HPLC.
Pharmacokinetics and statistics
Pharmacokinetic values were calculated from each individual 
set of data using WinNonlin, standard edition, version 1.1 
(Pharsight Corporation, Mountain View, CA) and the non-
compartmental method. The relative oral bioavailability of 
curcumin was calculated according to the equation:
Relative BA (%) =   100 × [(AUCformulation/doseformulation) 
/(AUCcurcumin/dosecurcumin)]
The pharmacokinetic results are represented as the 
mean ± standard error. The statistical analysis was performed 
by t-test (SPSS version 10.0, SPSS Inc, Chicago, IL) to 
compare different groups. The level of statistical significance 
was set at P , 0.05.
Results
Characteristics of LMw-NPC  
and HMw-NPC
The properties of the LMw-NPC and HMw-NPC are sum-
marized in Table 1. The zeta potential refers to the surface 
charge on the nanoparticles and the polydispersity index is the 
size distribution, indicating the degree of similarity between 
the nanoparticles, such that a smaller polydispersity index 
indicates that the particles are similar in size. Nanoparticles 
containing curcumin were prepared using a high-pressure 
emulsification-solvent evaporation procedure with PLGA 
as the encapsulating material. A negative zeta potential 
and smaller polydispersity index was obtained (−12.2 mV 
and 0.076 for LMw-NPC versus −14.1 mV and 0.068 for 
HMw-NPC). The sizes of the LMw-NPC and HMw-NPC 
were 166 ± 7.4 nm and 163 ± 4.2 nm, respectively. The 
encapsulation efficiency of both nanoformulations was nearly 
45%. According to the results, there was no statistically signifi-
cant difference in particle characteristics between LMw-NPC 
and HMw-NPC. As in our previous studies,3,17 similar proper-
ties of nanoparticles were found in the different batches when 
complied with standard procedures to prepare these LMw-NPC. 
Therefore, our study results were confirmed to be replicable 
and were well validated. Figure 1 shows the TEM images 
of LMw-NPC and HMw-NPC. The morphology of the 
curcumin nanoparticles was either ellipsoid or spherical, 
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Table 1 Effects of different molecular weights on nanoparticle characteristics
Particle size  
(nm)
Polydispersity  
index
Zeta potential  
(mV)
Encapsulation   
efficiency (%)
LMw-NPC 166 ± 7.4 0.076 ± 0.009 −14.1 ± 1.6 46.1 ± 3.7
HMw-NPC 163 ± 4.2 0.068 ± 0.012 −12.2 ± 1.0 45.0 ± 4.1
Note: Data expressed as mean ± standard deviation (n = 3). 
Abbreviations: LMw-NPC, curcumin encapsulated in low molecular weight PLgA; HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
A
200 nm
200 nm
B
Figure 1 Morphology by transmission electron microscopy of curcumin nanoparticles. (A) LMw-NPC and (B) HMw-NPC.
Abbreviations: LMw-NPC, curcumin encapsulated in low molecular weight PLgA; HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
and the diameter results were similar to the data observed 
by dynamic light scattering (below 200 nm) for both LMw-
NPC and HMw-NPC. Our TEM data are also consistent with 
those reported by Liang et al and Chang et al,19,20 with regard 
to the nanoparticles being a bright color and surrounded by 
a dark shadow. Our curcumin-loaded PLGA nanoparticles 
were well prepared and could be used in our subsequent 
pharmacokinetic study.
Validation of HPLC analytic method
The HPLC method was developed to investigate curcumin 
in rat plasma samples. Figure 2A–E shows the chromato-
grams of blank rat matrices, and Figure 2F–J shows the 
chromatograms of rat biosamples containing the internal 
standard and curcumin after administration of HMw-NPC. 
The retention times were approximately 6.5 and 22 minutes 
for the internal standard and curcumin, respectively, with 
no obvious interference peak in the blank chromatograms. 
These results suggest that the HPLC analytical conditions 
provided good separation and selectivity for curcumin and 
the internal standard in the experimental matrices. The vali-
dation methods were for linearity, limit of detection, limit of 
quantification, precision, accuracy, and extraction recovery. 
The calibration curves for plasma, feces, urine, serosal fluid, 
and sac tissue showed good linearity (r2 . 0.995) over the 
range of 0.01–2.5 µg/mL. The limits of detection and quan-
tification for curcumin were determined to be 0.005 µg/mL 
and 0.01 µg/mL, respectively. Intra-assay and interassay 
precision (% RSD and accuracy [% bias]) of curcumin 
measurements in each rat matrix were ±15%. Extraction 
of curcumin at low, medium, and high concentration in rat 
plasma, feces, urine, serosal fluid, and sac tissue was at least 
90%. These results indicate that the analytical and extraction 
methods used for curcumin and the internal standard were 
reliable for the following pharmacokinetic study.
Bioavailability and pharmacokinetics
Mean concentrations of curcumin in rat plasma at different 
times after oral administration of conventional curcumin 
(1 mg/kg) and LMw-NPC and HMw-NPC (50 mg/kg) are 
shown in Figure 3. Curcumin could be detected in plasma 
for 6 hours after oral ingestion of conventional curcumin 
and of LMw-NPC, but the retention time in rat plasma 
was prolonged to 8 hours for the HMw-NPC formulation. 
Table 2 shows significant increases in Cmax (from 0.028 for 
curcumin alone to 0.042 for LMw-NPC to 0.057 µg/mL for 
HMw-NPC) and area under the concentration-time curve 
(AUC) per dose (from 0.0062 to 0.15 to 0.25, respectively), 
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indicating that the absorption of curcumin increased when it 
was encapsulated in a nanoformulation. In addition, the rela-
tive bioavailability of HMw-NPC was 40-fold and 1.67-fold 
higher than that of conventional curcumin and LMw-NPC, 
respectively (Table 2). This indicates that the HMw-PLGA 
nanoformulation achieved markedly better absorption of 
curcumin compared with LMw-PLGA. Furthermore, after 
oral administration of HMw-NPC, the Tmax of curcumin was 
15 minutes shorter than that of the other curcumin formula-
tions (see Table 2). These results indicate that the relative 
bioavailability of curcumin was increased at a shorter Tmax, 
indicating that Tmax was closely related to the bioavailability 
of curcumin.
Without nanoformulation, the accumulated percentage 
of unabsorbed curcumin in feces approached 90% and in 
urine was almost 0% (Figure 4), implying that there was low 
absorption of curcumin in the gastrointestinal tract. PLGA 
encapsulation reduced the amount of curcumin in feces (from 
90% for curcumin alone to 40% for LMw-PLG to 20% for 
HMw-PLGA) and increased the amount of curcumin in urine 
(from near 0% to 0.07% to 0.16%), respectively, indicating 
that the absorption of curcumin was enhanced after PLGA 
formulation. These excretion results confirmed the pharma-
cokinetic parameters of the oral study, ie, the absorption of 
curcumin was significantly increased by both LMw-PLGA 
and HMw-PLGA formulation.
Ex vivo absorption
To understand better the relationship between relative 
bioavailability and Tmax for different molecular weights of 
PLGA-encapsulated curcumin and to explore the possible 
reasons for this, an ex vivo absorption study was undertaken. 
The concentration of curcumin absorbed from the incuba-
tion medium into the sac tissue and then into the serosal 
fluid is shown in Figure 5. When samples of the reverted 
sac of rat small intestine were incubated with conventional 
curcumin, LMw-NPC, and HMw-NPC, the amount of cur-
cumin absorbed from the curcumin nanoformulation was 
significantly increased in the duodenum and the ileum, but 
was not significantly different in the jejunum. The curcumin 
content was highest in the serosal fluid of the duodenum 
in the HMw-NPC group, followed by the LMw-NPC and 
conventional curcumin groups. The curcumin concentration 
from HMw-NPC in the serosal fluid of the duodenum was 
5.12-fold and 2.66-fold higher than from LMw-NPC and 
conventional curcumin, respectively (Figure 5A).
The absorption of curcumin, as determined by the sum 
of the amounts of curcumin in the serosal fluid, sac tissue, 
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Discussion
Nanoformulation technology has been extensively utilized 
in foods and nutritional supplements to increase the oral bio-
availability of active compounds, which may be beneficial for 
human health. However, there has been little investigation of 
how the materials used in the nanoformulation process affect 
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Figure  3  Concentration-time  curve  of  curcumin  in  rat  plasma  after  oral 
administration of curcumin at 1 g/kg, and LMw-NPC and HMw-NPC at 50 mg/kg 
(mean ± standard error, n = 4). 
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HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
Table 2 Pharmacokinetic parameters of curcumin in rat plasma 
after oral administration
Parameter Curcumin LMw-NPC HMw-NPC
1 g/kg 50 mg/kg 50 mg/kg
Tmax (min) 45 30 15
Cmax (µg/mL) 0.028 ± 0.01 0.042 ± 0.005a 0.057 ± 0.005a,b
AUC (min µg/mL) 6.23 ± 0.86 7.52 ± 0.63a 12.5 ± 0.82a,b
AUC/dose 0.0062 ± 0.003 0.15 ± 0.009a 0.25 ± 0.018a,b
Relative BA 1 24 40
Notes: Data expressed as mean ± standard error of the mean (n = 4).  aP , 0.05, 
significantly different from curcumin; bP , 0.05, significantly different from LMw-NPC.
Abbreviations: C max,  the  maximum  plasma  concentration;  Tmax,  time  to  Cmax;   
AUC,  area  under  the  concentration-time  curve;  BA,  bioavailability;  LMw-NPC, 
curcumin  encapsulated  in  low  molecular  weight  PLgA;  HMw-NPC,  curcumin 
encapsulated in high molecular weight PLgA.
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Figure 4 Cumulative excretion of curcumin in (A) feces and (B) urine after oral 
administration of curcumin at 1 g/kg, and LMw-NPC and HMw-NPC at 50 mg/kg 
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Abbreviations: LMw-NPC, curcumin encapsulated in low molecular weight PLgA; 
HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
and regions of the rat gut after incubation with curcumin 
and its formulations, is shown in Table 3. It can be seen 
that the amount of curcumin in the duodenum and ileum 
was significantly increased by curcumin encapsulated with 
PLGA. The HMw-PLGA formulation noticeably enhanced 
the absorption of curcumin in the duodenum compared 
with LMw-PLGA (from 0.63 µg to 0.89 µg) and with con-
ventional curcumin (from 0.47 µg to 0.89 µg). The ex vivo 
curcumin absorption results support the findings of the oral 
study, ie, that curcumin formulated with PLGA increased 
the absorption of curcumin in the intestine. Overall, HMw-
PLGA enabled considerably more curcumin absorption than 
LMw-PLGA.
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the oral pharmacokinetics of a product. This study found 
that changing the molecular weight of PLGA changes the 
pharmacokinetic parameters of conventional curcumin after 
oral administration. The present study also investigated the 
possible mechanism for this difference. The HPLC method 
was optimized and validated to obtain reliable pharmacoki-
netic data for curcumin21 (Figure 2).
The results of the animal study showed that the bio-
availability of curcumin was significantly increased by 
nanoformulation when using low or high molecular weight 
PLGA. The bioavailability of a compound in the body can 
be enhanced by decreasing its metabolism in the body or by 
increasing the absorption of the compound in the gastroin-
testinal tract.22 Transit time in the stomach and intestines is 
a major factor affecting absorption, and a longer intestinal 
transit time will generally enhance the absorption of a 
substance.23 In our study, the transit time of curcumin in 
the gastrointestinal tract was investigated to determine the 
effect of absorption. We undertook an excretion study using 
a metabolic cage, and the fecal excretion data (Figure 4A) 
showed that the time approaching the fastest rate and maxi-
mum accumulated amount of curcumin in feces was 18 hours, 
after which a plateau was maintained for 18–60 hours in all 
groups. This indicates that the time for curcumin to transit the 
rat gastrointestinal tract is independent of whether curcumin 
is formulated with or without LMw-PLGA or HMw-PLGA. 
This finding suggests that increased bioavailability is not due 
to the prolonged transit time of curcumin through the gas-
trointestinal tract as a result of formulation with PLGA. On 
the other hand, the hydrophilic characteristics of a compound 
will affect its absorption in the body. Merisko-Liversidge 
et al reported that nanoformulations increase the surface 
area and surface interactions of a compound compared 
with conventional forms, and that such formulations also 
increase the rate at which compounds are dissolved in the 
gastrointestinal tract, thereby improving the absorption of 
water-insoluble compounds.9 Therefore, increased bioavail-
ability of curcumin in the body may be attributable to faster 
dissolution after administration via a nanoformulation. We 
found that the Cmax, AUC, and AUC per dose for the HMw-
NPC group were significantly higher than for the LMw-NPC 
group (Table 2), even though the two groups had similar 
nanoparticle characteristics (Table 1). This may be because 
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Figure 5 Concentration of curcumin in (A) serosal fluid and (B) sac tissue of 
different small intestine region after incubation of curcumin, and LMw-NPC and 
HMw-NPC at 100 µg/mL for one hour. 
Notes: aP , 0.05, significantly different from curcumin; bP , 0.05, significantly different 
from LMw-NPC.
Abbreviations: LMw-NPC, curcumin encapsulated in low molecular weight PLgA; 
HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
Table 3 Amount of curcumin in sections of the small intestine 
after  incubation  of  curcumin,  LMw-NPC,  and  HMw-NPC  for   
60 minutes
Subdivision of  
small intestine
Curcumin amount after incubation (μg)
Curcumin LMw-NPC HMw-NPC
Serosal fluid + sac tissue
Duodenum 0.47 ± 0.04 0.63 ± 0.04a 0.89 ± 0.07a,b
Jejunum 1.01 ± 0.05 1.12 ± 0.06 1.11 ± 0.01
Ileum 0.85 ± 0.02 1.02 ± 0.02a 1.11 ± 0.04a
Notes: Data expressed as mean ± standard error (n = 4). aP , 0.05, significantly 
different from curcumin; bP , 0.05, significantly different from LMw-NPC.
Abbreviations: LMw-NPC, curcumin encapsulated in low molecular weight PLgA; 
HMw-NPC, curcumin encapsulated in high molecular weight PLgA.
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HMw-PLGA was more resistant than LMw-PLGA to the 
very acidic environment of gastric juice, which could reduce 
absorption by damaging the nanoparticle structure.24
It is noteworthy that different Tmax values were observed 
in the different curcumin formulation groups (Table 2). 
Denoting the time to maximum concentration of a drug in 
plasma, Tmax can be used as an indicator of the drug absorption 
rate, with smaller values indicating more rapid absorption.25 
According to our findings, the Tmax of conventional curcumin, 
LMw-NPC, and HMw-NPC was 45, 30, and 15 minutes, 
respectively. This indicates that absorption of HMw-NPC 
was faster than that of LMw-NPC, followed by   conventional 
curcumin. A previous study found that oral absorption of a 
drug is influenced by particle size, which affects the dissolu-
tion rate.26 However, the current study found no   statistically 
significant difference in particle size or any other particle 
characteristics between HMw-NPC and LMw-NPC (Table 1). 
Thus, particle size and other characteristics might not be 
responsible for the different bioavailability and absorption 
results for HMw-NPC and LMw-NPC. We hypothesized 
that the observed differences in   bioavailability and Tmax 
may be due to different absorption rates in   different portions 
of the gastrointestinal tract. To verify this hypothesis, we 
investigated ex vivo curcumin absorption from a portion of 
the small intestine.
It is known that the small intestine, composed of the 
duodenum, jejunum, and ileum, is the main site for digestion 
and absorption of water, nutrients, and electrolytes after a 
substance has been ingested orally.27 Our ex vivo absorption 
study demonstrated that conventional curcumin was absorbed 
mostly in the jejunum (Table 3). When encapsulated with 
PLGA, the amount of curcumin absorbed in the duodenum 
and ileum increased significantly, especially for HMw-NPC 
in the duodenum, but there was no significant difference in 
the rate of curcumin absorption in the jejunum with or without 
PLGA nanoformulation (Table 3).
Although DeSesso et al have reported that the bulk of 
absorption takes place in the duodenum and proximal half of 
the jejunum,23 our results indicate that the jejunum is the main 
area for absorption of curcumin. Encapsulating curcumin in 
a PLGA formulation will increase the amount of curcumin 
that can be absorbed in the duodenum, and even more so 
when curcumin is encapsulated with larger molecular weight 
PLGA. Therefore, increasing the absorption rate of curcumin 
in the duodenum may play an important role in increasing the 
relative bioavailability of curcumin formulated with PLGA. 
Rapid absorption of HMw-NPC in the duodenum would have 
shortened the Tmax when any of our study formulations were 
ingested. Previous research has shown that the duodenum is 
the main absorption site in the intestine.23 Our results dem-
onstrate that the bioavailability of a compound that cannot 
be effectively absorbed can be increased by high molecular 
weight PLGA, which is a significant and useful finding for 
nanoformulation. Possible transport mechanisms for this 
phenomenon will be investigated in a further study.
In conclusion, this study demonstrates that formulation 
with PLGA could enhance the bioavailability of a water-
insoluble polyphenol by increasing the absorption rate in 
the duodenum. In addition, different molecular weights of 
PLGA affect the pharmacokinetics of curcumin, which are 
closely related to the rate of absorption in the duodenum. 
These findings provide meaningful information for PLGA 
nanoformulations intended to increase the bioavailability 
of hydrophobic compounds in the design of drug delivery 
systems, and can be utilized in further preclinical and clini-
cal research.
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